沙格列汀和二甲双胍缓释片治疗2型糖尿病的研究进展

发布时间：2018-02-24 09:46

  本文关键词： 沙格列汀 二甲双胍 复方制剂 疗效 安全性　出处：《中国糖尿病杂志》2017年01期 　论文类型：期刊论文

【摘要】：沙格列汀与二甲双胍联用覆盖T2DM多重病理生理缺陷,不仅降低糖尿病患者血糖,且不增加低血糖风险,兼减重效应。UKPDS研究证实,二甲双胍有心血管保护作用,SAVOR研究明确了沙格列汀的心血管安全性。国内即将上市的沙格列汀二甲双胍缓释片复方制剂可实现每日一次口服给药,提高患者依从性,带来更多的临床获益。依据国内外最新指南,该复方制剂可作为HbA_1c≥7.5%的新诊断T2DM患者,或二甲双胍单药治疗血糖未达标患者的治疗选择之一。
[Abstract]:Combined use of salgletine and metformin to cover multiple pathophysiological defects in T2DM not only reduced blood glucose but also did not increase the risk of hypoglycemia in diabetic patients. Metformin has cardiovascular protective effect. The study of SAVOR has confirmed the cardiovascular safety of salgletine. The compound preparation of salglutin sustained-release tablets, which will be available in China, can be administered orally once a day and improve the compliance of patients. According to the latest guidelines at home and abroad, this compound preparation can be used as one of the treatment options for newly diagnosed T2DM patients with HbA_1c 鈮，

本文编号：1529792